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ABSTRACT
Introduction Nitrate- induced headache is common and 
may signify responsive cerebral vasculature. We assessed 
the relationship between nitrate headache and outcome in 
patients with acute stroke.
Materials and methods Patients were those randomised 
to glyceryl trinitrate (GTN) versus no GTN in the efficacy 
of nitric oxide in stroke trial. Development of headache by 
end of treatment (day 7), and functional outcome (modified 
Rankin Scale, primary outcome) at day 90, were assessed. 
Analyses are adjusted for baseline prognostic factors and 
give OR and mean difference (MD) with 95% CI.
Results In 4011 patients, headache was more common 
in GTN than control (360, 18.0% vs 170, 8.5%; p<0.001). 
Nitrate- related headache was associated with: younger 
age, female sex, higher diastolic blood pressure, non- 
total anterior circulation syndrome, milder stroke and 
absence of dysphasia (p<0.05). Nitrate headache was not 
associated with improved functional outcome (OR 0.90, 
95% CI 0.73 to 1.10, p=0.30) or death (day 90) (HR 0.64, 
95% CI 0.40 to 1.02, p=0.062), but reduced death or 
deterioration (day 7) (OR 0.45, 95% CI 0.25 to 0.82), death 
in hospital (OR 0.44, 95% CI 0.22 to 0.88) and improved 
activities of daily living (Barthel index, MD 3.7, 95% CI 0.3 
to 7.1) and cognition (telephone interview cognitive screen, 
MD 2.0, 95% CI 0.7 to 3.3) (day 90). Non- nitrate headache 
was not associated with death, disability or cognition.
Discussion and conclusion Development of a nitrate 
headache by day 7 after stroke may be associated with 
improved activities of daily living and cognitive impairment 
at day 90, which was not seen with non- nitrate headache.
INTRODUCTION
Headache is a common complication of stroke 
affecting ~25% of patients.1 Headache may be 
chronic, that is, preceding the stroke, or acute 
due to raised intracranial pressure, activation 
of nociceptive afferent nerves, altered cerebral 
perfusion and release of vasoactive substances.2 
Headache may also be an adverse reaction of 
certain drugs, in particular those that modulate 
the nitric oxide- cyclic guanosine monophos-
phate (NO- cGMP) system such as nitrates (eg, 
glyceryl trinitrate, GTN) or phosdiesterase-5 
inhibitors (PDE5- I, eg, dipyridamole) or the 
prostacyclin- cyclic adenosine monophos-
phate system such as phosdiesterase-3 inhibi-
tors (eg, cilostazol).3 Trials have reported the 
rapid development of headache with GTN in 
patients with acute stroke (8%–18%),4–8 and 
dipyridamole (11%–38%)9–12 and cilostazol 
(23%)13 14 in chronic stroke. Nitrate- induced 
headache is thought to be mediated through 
changes in cerebrovascular tone, and the symp-
toms are comparable to those experienced 
in acute attacks of migrainous headache.15 16 
Certainly, in migraine sufferers, nitrates can 
induce migraine headache, with increased 
intensity and greater dilation of cerebral vascu-
lature.15 16 Thus, nitrate- headache may be a 
useful marker of intact vascular reactivity and 
treatment response. Although nitrate and 
PGI2- type headaches can be mitigated in part 
through weaning- up doses, the development of 
such headache makes compliance with these 
drugs a challenge, in both trials and routine 
clinical practice.
Headache at stroke onset has been reported 
previously to be associated with a poor 
outcome.17 In contrast, development of a 
dipyridamole- related headache was associated 
with reduced stroke recurrence and symp-
tomatic intracranial haemorrhage (sICH) 
in patients with postischaemic stroke in the 
Prevention Regimen for Effectively Avoiding 
Second Strokes (PRoFESS) and the Second 
European Stroke Prevention Study (ESPS-2).12 
This finding raises the hypothesis that head-
ache occurring with other modulators of the 
NO- cGMP system might also improve outcome. 
However, no studies have specifically exam-
ined the relationship between nitrate head-
ache, cerebral perfusion and outcome in acute 
stroke. Thus, the mechanisms by which nitrate 
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headache may relate to improved outcomes in stroke 
remain unclear. Importantly, patients with nitrate headache 
may selectively benefit from nitrates through the mainte-
nance of vascular reactivity. Therefore, the presence of 
headache may have prognostic significance in acute stroke 
and facilitate targeted intervention for these individuals.
The efficacy of nitric oxide in stroke (ENOS) trial 
randomised participants to GTN versus no GTN.8 The 
primary outcome of the trial (modified Rankin scale, mRS 
at day 90) was neutral.8 In this preplanned secondary anal-
ysis,18 we aimed to test the hypothesis that GTN- related head-
ache is associated with an improved functional outcome.
METHODS
Aims
We assessed the relationship between nitrate headache and 
outcomes at day 7 and 90 in patients with acute stroke. As 
a comparison, the same measures were assessed in those 
randomised to no GTN. Specifically, we explored the 
following:
1. Baseline demographics and neuroimaging features 
of participants with nitrate headache, and differences 
with non- nitrate headache.
2. Changes in blood pressure and haemodynamics in ni-
trate and non- nitrate headache.
3. The relationship between nitrate headache and clini-
cal outcomes: function, death, death or deterioration, 
cognition, stroke recurrence, sICH, quality of life, ce-
rebral oedema, infarct extension, mood and length of 
stay.
ENOS trial
ENOS was an international randomised- controlled, patient- 
masked, blinded- endpoint trial; the protocol, statistical anal-
ysis plan, baseline characteristics and main results have been 
published previously.8 18–20 In brief, 4011 adult patients were 
recruited with acute stroke (ischaemic and haemorrhagic) 
within 48 hours of onset, with limb motor deficit and systolic 
blood pressure between 140 and 220 mm Hg. Participants 
were randomised (using stratification and minimisation) to 
receive transdermal GTN (5 mg) or no GTN (control) for 7 
days. The trial had national research ethics committee and 
regulatory approvals in each country, and informed written 
consent was taken for each patient (or proxy consent from 
a relative if the patient lacked capacity).19 All baseline char-
acteristics and other variables reported here, including the 
presence or absence of headache by day 7 (end of treat-
ment) and outcomes at day 90, were collected prospec-
tively. Headache was a patient reported outcome, occurring 
during GTN/no GTN treatment and necessitated inter-
vention (analgesia), including withdrawing GTN/no GTN 
treatment. Headache was defined by the participant and 
the investigator. Nitrate headache was considered defined 
as a headache occurring in the context of nitrate treatment, 
and non- nitrate headache where this occurred in the no 
GTN arm.
The primary end point for the main trial analysis was 
functional outcome (mRS). Data were collected on the 
following secondary outcome measures: death (day 7 and 
90, in hospital), death or deterioration (day 7), stroke 
recurrence (day 7), sICH (day 7), hypotension and hyper-
tension (day 7), Scandinavian Stroke Scale (SSS, day 7), 
cerebral oedema (day 7), infarct extension (day 7), compli-
cation (day 7), length of stay, Barthel index (day 7), cogni-
tion at day 90 (Mini- Mental State Examination (MMSE), 
Modified Telephone Interview for Cognitive Status, cate-
gory fluency), mood (Zung Depression Scale) and quality 
of life (European Quality of Life-5 dimensions (EQ- 5D), 
European Quality of Life- Visual Analogue Scale). A full 
description and definition of the outcome measures has 
been published previously.8 18 19
Statistical analysis
Nitrate headache was defined as a headache occurring 
in participants randomised to GTN; these headaches will 
have included some that were not related to nitrate treat-
ment, as occurred in the non- GTN group. All analyses were 
performed by intention to treat. Baseline characteristics 
were compared within randomised groups between those 
with and without a headache by day 7 using χ2 test (binary 
variables), and independent t- test (continuous variables). 
The relationship between the development of headache and 
outcomes within treatment groups was assessed using regres-
sion models comprising binary logistic regression (death, 
death or deterioration, sICH, stroke recurrence by day 7), 
Cox proportional regression (death up to day 90), ordinal 
logistic regression (mRS at day 9021), and multiple linear 
regression analysis (other continuous variables). Regression 
analyses were performed unadjusted, and adjusted for8: age, 
sex, premorbid mRS, previous stroke, diabetes mellitus, 
current nitrate use, time from onset to randomisation, 
systolic blood pressure, total anterior circulation syndrome 
(TACS), SSS score, stroke type, thrombolytic treatment, 
feeding status, and continuation of prestroke antihyperten-
sive drugs. The interactions between prespecified participant 
subgroups, headache and outcome (mRS) were assessed 
following adjustment using ordinal logistic regression with 
an interaction term. Time updated outcomes were produced 
for survival, where time in days was calculated from day- of- 
onset of headache to day- of- death and then categorised into 
dichotomous variables for those who died between days 0–7, 
8–30, 31–90 or more than 90 days after headache onset. Each 
time updated outcome was entered into a binary logistic 
regression model and the effect of headache on survival at 
the different time points was analysed.
Results are presented as OR, HR or mean difference 
with 95% CIs. ORs represent the increase in risk of an 
outcome measure with a headache at day 7. Analyses were 
conducted with SPSS (V.22 for Mac or Windows), and 
significance was set at p<0.05.
RESULTS
Of the 4011 participants randomised into ENOS, 4000 had 
data recorded on the presence or not of headache. Of these, 
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530 had a headache by day 7; headache was more common 
in patients randomised to GTN (360, 18.0%) as compared 
with those randomised to no GTN (170, 8.5%) (p<0.001). 
Eleven participants did not have data reported on head-
ache, therefore, the total number of participants included 
in this analysis was 4000. In participants randomised to GTN, 
Table 1 Baseline demographics by treatment group (GTN/no GTN), in patients with and without headache at day 7
GTN (n=1996) P value No GTN (n=2004) P value
Headache Yes No Yes No
No of patients (n) 360 (18.0) 1636 (82.0) 170 (8.5) 1834 (91.5)
Age (years) 66.6 (12.4) 71.1 (11.9) <0.005 67.6 (11.8) 70.6 (12.2) 0.002
Sex, female (%) 172 (47.8) 679 (41.5) 0.029 82 (48.2) 777 (42.4) 0.14
Pre- morbid mRS score 0 (1) 0 (0) 0.006 0 (0) 0 (1) 0.12
Medical history (%)
  Hypertension 220 (61.1) 1065 (65.1) 0.15 105 (61.8) 1211 (66) 0.26
  Stroke 51 (14.2) 262 (16) 0.38 22 (12.9) 255 (13.9) 0.73
  Diabetes mellitus 52 (14.4) 289 (17.7) 0.14 29 (17.1) 324 (17.7) 0.84
  Current nitrate use 18 (5) 69 (4.2) 0.51 6 (3.5) 61 (3.3) 0.89
Onset to randomisation (hours) 25.2 (12.5) 25.8 (12.9) 0.42 25.1 (12.5) 26.3 (12.9) 0.25
Haemodynamics
  Systolic BP (mm Hg) 166.7 (18.5) 167.5 (18.8) 0.46 168.4 (19.5) 167 (19.1) 0.36
  Diastolic BP (mm Hg) 91.6 (12.7) 89.3 (13) 0.002 89.2 (12.5) 89.4 (13.4) 0.88
  Heart rate, mean (bpm) 78.2 (14.8) 77.5 (14.8) 0.45 77.6 (14.3) 77.3 (14.7) 0.77
  Atrial fibrillation (%) 53 (14.7) 336 (20.5) 0.012 33 (19.4) 338 (18.4) 0.75
Syndrome
  TACS (%) 86 (23.9) 527 (32.2) 0.002 58 (34.1) 535 (29.2) 0.18
  LACS (%) 154 (42.8) 541 (33.1) 0.008 48 (28.2) 653 (35.6) 0.28
Dysphasia 90 (25.0) 704 (43.0) <0.005 59 (34.7) 750 (40.9) 0.12
Neglect/inattention 91 (26.6) 431 (30) 0.21 61 (40.7) 485 (29.6) 0.005
Hemianopia 74 (20.6) 297 (18.2) 0.89 51 (30) 313 (17.1) <0.005
SSS score (/58) 37.2 (11.2) 33.2 (13.4) <0.005 33.8 (11.9) 33.5 (13.4) 0.70
Stroke type (%)
  Ischaemic 287 (79.7) 1373 (83.9) 0.043 129 (75.9) 1544 (84.2) 0.12
  Haemorrhage 39 (10.8) 278 (17) 66 (38.8) 244 (13.3)
  Non stroke 2 (0.6) 11 (0.7) 7 (4.1) 19 (1)
Lesion side (%)
  Left 109 (45.0) 501 (47) 0.78 49 (43) 541 (45.3) 0.50
  Right 131 (54.1) 554 (51.9) 63 (55.3) 645 (54)
  Both 2 (0.8) 12 (1.1) 2 (1.8) 9 (0.8)
Feeding status, non- oral (%) 76 (21.1) 591 (36.1) <0.005 56 (32.9) 605 (33) 0.99
Neuroimaging adjudication
  White matter change (%) 116 (32.2) 701 (42.8) <0.005 64 (37.6) 763 (41.6) 0.16
  White matter score (/4) 0 (2) 0 (2) <0.005 0 (2) 0 (2) 0.18
  Atrophy (%) 272 (75.6) 1354 (82.8) <0.005 135 (79.4) 1464 (79.8) 0.24
  Atrophy score (/4) 2 (1) 2 (2) <0.005 2 (1) 2 (2) 0.007
  Previous stroke lesion (%) 194 (53.9) 992 (60.6) 0.006 81 (47.6) 1056 (57.6) 0.002
Alteplase 36 (10.1) 167 (10.2) 0.93 25 (14.9) 195 (10.7) 0.095
Continued antihypertensives (%) 81 (22.5) 432 (26.4) 0.009 38 (22.4) 486 (26.5) 0.26
Data are number (%), median (IQR) or mean (SD). Comparison by χ2, Kruskal- Wallis or independent t- test.
BP, blood pressure; GTN, glyceryl trinitrate; LACS, lacunar syndrome; mRS, modified Rankin Scale; SSS, Scandinavian Stroke Scale; TACS, 
total anterior circulation syndrome.
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those who developed a headache by day 7 were younger; 
more likely to be female; have higher diastolic blood pres-
sure; more likely to have a mild stroke (higher baseline SSS 
score, more oral feeding), lacunar syndrome or ischaemic 
stroke; and less likely to have dysphasia or atrial fibrillation 
(table 1). In the control (no GTN) group, patients devel-
oping a headache were younger and were more likely to 
have neglect or hemianopia than those without headache. 
In respect of baseline imaging, nitrate- related headache 
was associated with less white matter change and lower 
white matter score; less atrophy; and fewer previous stroke 
lesions (table 1). Participants with a non- nitrate headache 
had fewer previous stroke lesions and a lower atrophy score 
on imaging than patients in the control group without 
headache.
Of the patients who developed a headache, 13 (3.6%) in 
the GTN group and 2 (1.2%) in the non- GTN group had 
withdrawn from treatment by day 7 (p=0.12). There was 
no significant difference between the treatment groups for 
time from randomisation to development of the headache: 
GTN 1.2 (2.1) days vs no GTN 1.9 (6.9), mean difference 
−0.7 days (95% CI −1.8, 0.4 days, p=0.20). Changes in blood 
Table 2 Relationship between outcome and headache by day 7, in participants who received GTN
Headache Total Yes No
Unadjusted OR/
HR/MD
(95% CI) 2p
Adjusted OR/HR/
MD
(95% CI) P value
Day 7 (%)*
  Death 1996 2 (0.6) 59 (3.6) 0.15 (0.04 to 0.61) 0.008 0.24 (0.06 to 1.00) 0.050
  Deterioration/death 1992 14 (3.9) 166 (10.2) 0.36 (0.21 to 0.62) <0.001 0.45 (0.25 to 0.82) 0.009
  Recurrence 1995 3 (0.8) 39 (2.4) 0.34 (0.11 to 1.12) 0.076 0.41 (0.12 to 1.36) 0.15
  sICH 1996 4 (1.1) 18 (1.1) 1.01 (0.34 to 3.00) 0.99 1.15 (0.36 to 3.69) 0.82
  Hypotension 1996 6 (1.7) 50 (3.1) 0.54 (0.23 to 1.26) 0.16 0.52 (0.22 to 1.24) 0.14
  Hypertension 1996 40 (11.1) 99 (6.1) 1.94 (1.32 to 2.86) 0.001 1.81 (1.19 to 2.76) 0.006
  SSS (/58) 1992 43.4 (13) 38.2 (16.3) 5.25 (3.45 to 7.05) <0.001 0.88 (−0.25 to 2.01) 0.13
SAEs by day 7 (%)*
  Cerebral oedema 1996 4 (1.1) 11 (0.7) 1.66 (0.53 to 5.24) 0.39 2.90 (0.77 to 10.85) 0.12
  Complication 1996 0 (0) 22 (1.3) – – – –
  Extension 1996 5 (1.4) 48 (2.9) 0.47 (0.18 to 1.18) 0.11 0.53 (0.21 to 1.38) 0.19
Hospital events
  Length of stay (days)† 1988 17.8 (20.7) 21.4 (23.9) −3.6 (−6.0 to −1.1) 0.009 0.4 (−2.1 to 2.9) 0.76
  Death (%)‡ 1996 10 (2.8) 149 (9.1) 0.29 (0.15 to 0.55) <0.001 0.44 (0.22 to 0.88) 0.020
Day 90
  Death (%)‡ 1991 21 (5.8) 210 (12.9) 0.42 (0.27 to 0.67) <0.001 0.64 (0.40 to 1.02) 0.062
  mRS (/6)§ 1996 2.6 (1.6) 3.2 (1.7) 0.58 (0.47 to 0.70) <0.001 0.90 (0.73 to 1.10) 0.30
  Barthel Index (/100)† 1980 77 (31.4) 63 (39.0) 14.0 (10.2 to 17.7) <0.001 3.7 (0.3 to 7.1) 0.034
  MMSE (/30)† 1003 13.8 (6) 10.6 (7.6) 3.2 (2.2 to 4.2) <0.001 1.5 (0.6 to 2.4) 0.002
  TICS- M (/30)† 993 18.5 (8.8) 14 (10.6) 4.5 (3.1 to 5.9) <0.001 2.0 (0.7 to 3.3) 0.003
  Category fluency† 1172 11.6 (7.5) 8.7 (97.7) 2.9 (1.8 to 4.0) <0.001 1.3 (0.3 to 2.2) 0.008
  ZDS (/102.5)† 1630 54.6 (20.5) 59.1 (24.3) −4.5 (−7.4 to -1.6) 0.002 −0.9 (−3.5 to 1.7) 0.48
  EQ- 5D/HUS (/1)† 1975 0.52 (0.39) 0.45 (0.4) 0.08 (0.03 to 0.12) 0.001 −0.01 (0.03 to 0.95) 0.69
  EQ- VAS (/100)† 1717 60.9 (28.0) 55.5 (31.3) 1.9 (1.6 to 9.1) 0.005 −0.5 (−3.8 to 2.8) 0.76
Adjusted results are shown, with adjustment for age, sex, premorbid mRS score, previous stroke, diabetes mellitus, current nitrate use, time 
from onset to randomisation systolic blood pressure, total anterior circulation syndrome, Scandinavian Stroke Scale Score, stroke type, 
thrombolytic treatment, feeding status and continuation of prestroke antihypertensive drugs.
Data are number (%) or mean (SD), and OR, HR or mean difference (95% CIs).
*Comparisons by binary logistic regression.
†Multiple linear regression.
‡Cox regression.
§Ordinal logistic regression.
EQ- 5D, European Quality of Life-5 dimensions; EQ- VAS, European Quality of Life- Visual Analogue Scale; HUS, health utility status; ICH, 
symptomatic intracranial haemorrhage; MD, mean difference; mRS, modified Rankin Scale; SAE, serious adverse event; SSS, Scandinavian 
Stroke Scale; TICS, Modified Telephone Interview for Cognitive Status; tMMSE, telephone Mini- Mental State Examination; ZDS, Zung 
Depression Scale.
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pressure and other haemodynamic measures between base-
line and 1–2 hours postfirst dose (day 1) did not differ by 
the presence or absence of a headache in either treatment 
group (online supplemental table 1).
In adjusted analyses, the presence of nitrate- related 
headache was not associated with an improved functional 
outcome at 90 days: adjusted OR 0.90 (95% CI 0.73 to 1.10; 
p=0.30) (table 2 and figure 1), or with a better survival up 
to 90 days: adjusted HR 0.64 (95% CI 0.40 to 1.02; p=0.062) 
(table 2 and figure 2). However, the presence of a nitrate- 
related headache by day 7 was associated with a lower risk 
of death or deterioration at day 7 and death in hospital 
(table 2). Further, nitrate- related headache was associated 
with higher/better scores at day 90 for the Barthel Index, 
MMSE and Telephone Interview of Cognitive Status. A 
tendency to less early recurrence was also apparent for 
patients developing a nitrate- related headache (table 2).
In patients randomised to no GTN, the presence of 
a headache by day 7 was not associated with a change in 
functional outcome at 90 days or with a change in survival, 
but it was associated with a longer length of stay in hospital, 
and lower health utility status (as derived from the EQ- 5D) 
at day 90 (online supplemental table 2). Hypertension was 
significantly associated with both nitrate and non- nitrate 
headache, but cerebral oedema was only more common 
in patients with non- nitrate headache (table 2 and online 
supplemental table 2).
When assessing interactions between headache, baseline 
factors, and outcome (mRS), participants randomised to 
GTN were more likely to have a good outcome if they were 
older (figure 3). In patients who did not receive GTN, a 
better outcome was apparent in older participants and men 
who developed a (non- nitrate) headache (online supple-
mental figure 1).
Finally, in a time- updated analysis, nitrate headache was 
associated with significantly lower risk of death at between 
0 and 7 days after headache onset, but not at other time 
points, (online supplemental tables 3 and 4). There was 
no association with non- nitrate headache on survival at 
different time points, (online supplemental tables 3 and 
4). Nitrate headache was associated with increased risk 
of death, beyond 90 days after headache onset, (online 
supplemental tables 3 and 4).
DISCUSSION
This prespecified subgroup analysis of the ENOS trial18 
reveals that reported headache after stroke and within 7 
days is relatively common (8.5%) and that GTN, an organic 
nitrate that releases nitric oxide, more than doubles this 
rate to 18.0%. Although development of a nitrate head-
ache within 7 days of randomisation was not associated 
with improvement in functional outcome or increased 
survival by 90 days, it was associated with reduced death, 
and deterioration by day 7, reduced death in hospital, and 
better activities of daily living and cognitive impairment at 
day 90. Despite the lack of association between headache 
and the primary outcome (mRS), activities of daily living as 
assessed by the Barthel Index, were significantly improved 
in the nitrate headache group. Although both scales are 
a measure of disability, the greater focus on specific tasks 
in the Barthel Index, rather than a global measure of disa-
bility provided by the mRS, may be more sensitive to subtle 
changes, particularly in mild to moderate stroke.22 23
The presence of a headache after stroke onset has been 
associated variously with poor clinical outcome17 and 
reduced risk of recurrence.12 In the PRoFESS secondary 
prevention trial,11 development of headache with dipyrid-
amole (a phosphodiesterase inhibitor [PDEI]) was associ-
ated with a reduction in stroke recurrence.12 A similar result 
was seen in the ESPS-2 trial.10 A tendency to a lower rate of 
recurrence was also present in our patients with a nitrate 
Figure 1 Distribution of modified Rankin Scale scores 
at day 90 by presence or absence of headache by day 7 
for the GTN group. Data are percentage of total patients. 
Comparison by ordinal logistic regression. Adjusted OR 0.9 
(95% CI 0.73 to 1.1), p=0.3 (no headache: n=1631, headache: 
n=359). GTN, glyceryl trinitrate.
Figure 2 Survival curves over 90 days of follow- up for 
the glyceryl trinitrate (GTN) group. Comparison by Cox 
proportional regression. Adjusted HR 0.64 (95% CI 0.40 to 
1.02), p=0.062.
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headache, although this did not translate into a better func-
tional outcome or survival. Possible reasons for the stronger 
effect on stroke recurrent in the PRoFESS and ESPS-2 trials 
may be: longer duration of follow- up, increased number of 
events (more statistical power), focus on stroke recurrence 
rather than functional outcome, or the use of alternative 
nitrates. The development of headache in response to GTN 
suggests the ability of the cerebral vasculature to dilate,12 
a mechanism common to migrainous headache.24 Dila-
tion of the dysfunctional vasculature may increase collat-
eral vascular efficiency, cerebral blood flow (CBF) and 
perfusion to viable ischaemic penumbra.25–27 Nevertheless, 
studies of CBF and CBF- velocity did not find, overall, any 
changes related to administration of GTN.5 6
The strengths of this prespecified substudy of the ENOS 
trial are the large sample size and completeness of data 
in the ENOS trial, this reducing the risk that the findings 
are purely due to chance; the international, multicentre 
setting of the trial which increases the external validity of 
the findings; and the possibility to adjust in for a number of 
prospectively collected prognostic variables, especially clin-
ical variables at baseline.
Nevertheless, a number of caveats need highlighting. 
First, patients who developed a nitrate- headache differed 
from those who did not have a headache and some of these 
differences will have favoured outcome in the nitrate- 
headache group, especially lower age and stroke severity, 
and lacunar stroke syndrome. Statistical adjustment will 
have corrected, in part, for some of these differences. 
Second, the association of nitrate headache with mild 
stroke (high SSS, non- TACS) may be real but could alter-
natively reflect that patients with severe stroke or a TACS 
may have headache but not be able to report it, perhaps 
due to the presence of dysphasia, confusion or reduced 
level of consciousness. Similarly, ENOS was patient—
but not staff- masked; hence, staff may have been more 
likely to monitor and report headache in those patients 
randomised to GTN. Finally, data were not collected on 
the time to headache development, so it is unclear if head-
ache occurring within 7 days was during the initial or later 
phase of nitrate treatment. Nitrate headache typically 
occurs within 6 hours of treatment onset and abates by 
5–7 days.28 Nitrate headaches occurring within 1 hour of 
treatment are usually mild to moderate with spontaneous 
resolution, where- as migraine- type headaches associated 
with nitrate are delayed (onset 3–6 hours) and are usually 
more severe and persistent.28 Nitrate tolerance (loss of 
vasodilation) usually occurs within 24–48 hours of treat-
ment, and it remains unclear why headache persists after 
this time.28 Further work, exploring the time to headache 
onset could identify whether earlier or later onset nitrate- 
headaches are associated with improved outcomes after 
stroke.
In conclusion, the development of nitrate- related head-
ache at day 7 after acute stroke may have important prog-
nostic implications and was associated with reduced death, 
deterioration at day 7, and improved activities of daily living 
and cognition scores at 90 days. These findings will be reas-
sessed in the ongoing rapid implementation of GTN in 
hypertensive stroke trial-2.
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Supplementary Table 1. Change in haemodynamic measures from baseline to day 1 by treatment group and 
development of headache. 
Data are change from baseline (standard deviation), mean difference (95% confidence interval). 
 
  GTN    No GTN   
 Headache No 
headache 
MD (95% CI) P 
value 
Headache No 
headache 
MD (95% CI) P 
value 
SBP (mmHg) -9.9 
(16.92) 
-10.7 
(19.6) 
0.85 (-1.37, 
3.07) 
0.41 
-2.1 
(19.3) 
-3.7 (18.3) 
1.56 (-1.36, 
4.48) 
0.30 
DBP (mmHg) -5.8 
(11.92) 
-5.1 (12.5) 
-0.62 (-2.06, 
0.82) 
0.40 
-0.6 
(11.1) 
-1.7 (11.7) 
1.06 (-0.79, 
2.91) 
0.26 
Heart rate 
(bpm) 
1.4 
(10.49) 
1.2 (10.6) 
0.18 (-1.05, 
1.41) 
0.77 1.1 (8.9) -0.1 (10.0) 
1.21 (-0.36, 
2.79) 
0.13 
PP (mmHg) -4.1 
(13.69) 
-5.6 (14.8) 
1.47 (-0.22, 
3.16) 
0.089 
-1.5 
(14.4) 
-2.0 (14.7) 
0.50 (-1.84, 
2.84) 
0.68 
MAP (mmHg) -7.1 
(12.18) 
-7.0 (13.6) 
-0.13 (-1.67, 
1.41) 
0.87 
-1.1 
(12.7) 
-2.3 (12.4) 
1.22 (-0.75, 
3.2) 
0.23 
RPP 
(mmHg.bpm) 
-554 
(2206) 
-611 
(2418) 
56.6 (-219.6, 
332.8) 
0.69 
38.6 
(2232) 
-296 
(2260) 
335.0 (-25.5, 
695.4) 
0.069 
 
bpm: beats per minute; CI: confidence intervals; DBP: diastolic blood pressure; MAP: mean arterial pressure; MD: mean 
difference; PP: pulse pressure; RPP: rate pressure product (= systolic BP x heart rate); SBP: systolic blood pressure 
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Supplementary Table 2. Relationship between outcome and headache by day 7, in participants who did not receive 
GTN. 
Data are number (%) or mean (standard deviation), and odds ratio, hazard ratio or mean difference (95% confidence intervals). 
Comparisons by binary logistic regression1, multiple linear regression2, Cox regression3, or ordinal logistic regression4. Unadjusted 
and adjusted results are shown, with adjustment for age, sex, pre-morbid modified Rankin scale, previous stroke, diabetes 
mellitus, current nitrate use, time from onset to randomisation systolic blood pressure, total anterior circulation syndrome, 
Scandinavian Stroke Scale, stroke type, thrombolysis given, feeding status, and randomisation to continue versus stop pre-stroke 
antihypertensive drugs. 
 
Headache Total Yes No 
Unadjusted OR/HR/MD 
(95% CI) 
2p 
Adjusted OR/HR/MD 
(95% CI) 
2p 
Day 7 (%)1        
Death 2004 3 (1.8) 55 (3) 0.58 (0.18, 1.88) 0.36 0.75 (0.22, 2.51) 0.64 
Deterioration/death 1999 12 (7.1) 186 (10.2) 0.67 (0.37, 1.23) 0.2 0.65 (0.35, 1.23) 0.19 
Recurrence 2002 3 (1.8) 28 (1.5) 1.16 (0.35, 3.85) 0.81 1.24 (0.36, 4.26) 0.73 
sICH 2004 1 (0.6) 17 (0.9) 0.63 (0.08, 4.78) 0.66 0.7 (0.09, 5.61) 0.74 
Hypotension 2004 0 (0) 16 (0.9) - - - - 
Hypertension 2004 25 (14.7) 132 (7.2) 2.22 (1.4, 3.52) 0.001 1.96 (1.21, 3.19) 0.006 
SSS (/58) 1999 39.6 (15.3) 38.4 (16.4) 1.3 (-1.3, 3.8) 0.33 0.8 (-0.7, 2.3) 0.31 
SAEs by day 7 (%)1        
Cerebral oedema 2004 4 (2.4) 15 (0.8) 2.92 (0.96, 8.91) 0.06 4.94 (1.36, 17.94) 0.015 
Complication 2004 0 (0) 11 (0.6) - - - - 
Extension 2004 1 (0.6) 32 (1.7) 0.33 (0.05, 2.45) 0.28 0.37 (0.05, 2.78) 0.34 
Hospital events        
Length of stay (days)2 1997 25.1 (27.5) 20.7 (23.4) 4.4 (0.1, 8.7) 0.020 5.5 (2.0, 9.0) 0.002 
Death (%)3 2004 10 (5.9) 151 (8.2) 0.7 (0.36, 1.34) 0.28 0.96 (0.47, 1.98) 0.92 
Day 90        
Death (%)3 1995 17 (10.1) 246 (13.5) 0.72 (0.43, 1.21) 0.21 0.93 (0.56, 1.53) 0.77 
mRS (/6)4 2004 3.12 (1.6) 3.11 (1.8) 1.03 (0.78, 1.36) 0.85 1.15 (0.89, 1.4) 0.35 
Barthel Index (/100)2 1982 65.6 (35.9) 63.1 (39.7) 2.53 (-3.23, 8.29) 0.43 -2.4 (-5.00, 4.52) 0.92 
MMSE (/30)2 1021 12.2 (7) 10.7 (7.8) 0.8 (0.00, 3.1) 0.066 0.4 (-0.9, 1.6) 0.57 
TICS-M (/30)2 1013 15.8 (9.5) 14.4 (10.9) 1.5 (-0.7, 3.6) 0.22 -0.2 (-2.0, 1.6) 0.81 
Category fluency2 1185 10.2 96.9) 9.1 (8) 1.1 (-0.2, 2.5) 0.14 0.2 (-1.1, 1.5) 0.77 
ZDS (/102.5)2 1615 58.2 (23.4) 58.9 (24.7) -0.7 (-5.0, 3.7) 0.76 1.0 (-2.7, 4.7) 0.58 
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EQ-5D / HUS (/1)2 1968 0.42 (0.4) 0.46 (0.4) -0.04 (-0.10, 0.03) 0.24 -0.06 (-0.11, 0.01) 0.024 
EQ-VAS (/100)2 1715 57.7 (30.6) 55.4 (31.7) 2.8 (-3.1, 7.7) 0.41 -0.4 (-5.00, 4.3) 0.88 
 
EQ-5D: European Quality of Life-5 dimensions; EQ-VAS: European Quality of Life-Visual Analogue Scale; HUS: health utility 
status; mRS: modified Rankin Scale; sICH: symptomatic intracranial haemorrhage; SSS: Scandinavian Stroke Scale; tMMSE: 
telephone Mini Mental State Examination; TICS: Modified Telephone Interview for Cognitive Status; ZDS: Zung Depression Scale. 
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Supplementary Table 3. Relationship between headache and death in patients who received GTN, using time updated 
co-variates (days 0-7, days 8-30, day 31-90 to death after headache occurrence). 
Data are number (%), and odds ratio. Comparisons by binary logistic regression. Unadjusted and adjusted results are shown, with 
adjustment for age, sex, pre-morbid modified Rankin scale, previous stroke, diabetes mellitus, current nitrate use, time from 
onset to randomisation systolic blood pressure, total anterior circulation syndrome, Scandinavian Stroke Scale, stroke type, 
thrombolysis given, feeding status, and randomisation to continue versus stop pre-stroke antihypertensive drugs. 
 
 
 
 
 
 
 
Headache Total Yes No 
Unadjusted OR/HR/MD 
(95% CI) 
2p 
Adjusted OR/HR/MD 
(95% CI) 
2p 
Death (%)        
Day 0-7 442 2 (3.8) 66 (17) 0.19 (0.05, 0.81) 0.024 0.21 (0.05, 0.94) 0.042 
Day 8-30 441 80 361 0.91 (0.43, 1.96) 0.82 0.78 (0.34, 1.79) 0.56 
Day 31-90 441 56 385 0.85 (0.34, 2.08) 0.72 0.88 (0.32, 2.43) 0.8 
Day 90+ 441 206 236 2 (1.09, 3.68) 0.026 2.38 (1.17, 4.83) 0.017 
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Supplementary Table 4. Relationship between headache and death in patients who did not receive GTN, using time 
updated co-variates (days 0-7, days 8-30, and days 31-90 death after headache occurrence). 
Data are number (%) and odds ratio. Comparisons by binary logistic regression. Unadjusted and adjusted results are shown, with 
adjustment for age, sex, pre-morbid modified Rankin scale, previous stroke, diabetes mellitus, current nitrate use, time from 
onset to randomisation systolic blood pressure, total anterior circulation syndrome, Scandinavian Stroke Scale, stroke type, 
thrombolysis given, feeding status, and randomisation to continue versus stop pre-stroke antihypertensive drugs. 
Headache Total Yes No 
Unadjusted OR/HR/MD 
(95% CI) 
2p 
Adjusted OR/HR/MD 
(95% CI) 
2p 
Death (%)        
Day 7 442 2 (5.3) 59 (13.8) 0.35 (0.08, 1.47) 0.15 0.24 (0.05, 1.12) 0.070 
Day 8-30 462 96 366 1.02 (0.45, 2.3) 0.97 1.04 (0.43, 2.48) 0.93 
Day 31-90 462 72 390 0.8 (0.3, 2.12) 0.65 0.93 (0.33, 2.6) 0.89 
Day 90+ 464 232 232 1.59 (0.81, 3.14) 0.18 1.72 (0.8, 3.71) 0.17 
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Supplementary Figure 1. Distribution of modified Rankin Scale scores at day 90 by presence or absence of headache 
by day 7 for the no GTN group. 
Data are percentage of total patients. Comparison by ordinal logistic regression. 
 
No GTN group:  Adjusted odds ratio 1.15 (0.89, 1.4), 2p=0.35 (No headache: n=1826, headache: n=169). 
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Supplementary Figure 2. Survival curves over 90 days of follow up for no GTN 
treatment group. 
Comparison by Cox proportional regression. 
 
Adjusted hazard ratio 0.93 (0.56, 1.53), p=0.77. 
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Supplementary Figure 3. Sub-group analysis for the interaction between 
baseline parameters and headache on the modified Rankin Scale in patients 
who did not receive GTN. 
Data are odds ratio (95% confidence interval), modelled using ordinal logistic 
regression with an interaction term and with adjustment (variables listed in statistics 
section). HTN: hypertension; OTR: on treatment randomisation; SBP: systolic blood 
pressure; SSS: Scandinavian Stroke Scale; TACS: total anterior circulation syndrome. 
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